Bank of New York Mellon’s Theriva Biologics TOVX Stock Holding History

Bank of New York Mellon’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8	Closed	-$17K	–	4268
2018 Q2	$17K	Sell	8 -3	-27%	-$6.89K	﹤0.01%	4182
2018 Q1	$31K	Buy	11 +2	+22%	+$7.61K	﹤0.01%	4235
2017 Q4	$38K	Buy	9 +1	+13%	+$6.25K	﹤0.01%	4236
2017 Q3	$68K	Hold	8	–	–	﹤0.01%	4054
2017 Q2	$41K	Sell	8 -22	-73%	-$110K	﹤0.01%	4157
2017 Q1	$166K	Buy	30 +1	+3%	+$6.98K	﹤0.01%	3924
2016 Q4	$196K	Hold	29	–	–	﹤0.01%	3911
2016 Q3	$429K	Sell	29 -4	-12%	-$59.9K	﹤0.01%	3610
2016 Q2	$525K	Buy	33 +24	+267%	+$452K	﹤0.01%	3516
2016 Q1	$194K	Hold	9	–	–	﹤0.01%	3793
2015 Q4	$188K	Hold	9	–	–	﹤0.01%	3880
2015 Q3	$186K	Hold	9	–	–	﹤0.01%	3930
2015 Q2	$230K	Hold	9	–	–	﹤0.01%	3852
2015 Q1	$173K	Buy	9 +5	+125%	+$89.3K	﹤0.01%	3928
2014 Q4	$54K	Hold	4	–	–	﹤0.01%	4136
2014 Q3	$63K	Hold	4	–	–	﹤0.01%	4133
2014 Q2	$61K	Buy	+4	New	+$63.4K	﹤0.01%	4059

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

Bank of New York Mellon's TOVX Position: Q3 2018 in Review

Bank of New York Mellon sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 8 shares — an estimated $17K sold.

Bank of New York Mellon first reported a position in TOVX in Q2 2014 and held it in 17 quarters. The position peaked at $525K in Q2 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Bank of New York Mellon reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Bank of New York Mellon sold 8 Theriva Biologics shares in Q3 2018, an estimated $17K.
Bank of New York Mellon first reported a position in Theriva Biologics in Q2 2014 and held it in 17 quarters.
Bank of New York Mellon's Theriva Biologics position peaked at $525K in Q2 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Bank of New York Mellon's 13F filing for Q3 2018, filed 9 Nov 2018.